The MS Society has been recognised as the only charity in the country to join a new awards initiative by the Fulbright Commission which aims to develop the talent of some of Britain’s most promising medical researchers. Today, at a service to mark the 60th anniversary of the Fulbright Treaty, […]
Filed under: Multiple Sclerosis on September 30th, 2008 | Comments Off
Living with post-traumatic stress disorder (PTSD) can strain any relationship - sometimes to the point of violence against a loved one. University of Arkansas psychologist Matthew T. Feldner is part of two national research projects aimed at preventing relationship aggression in couples coping with PTSD and treating this type of aggression when it has already […]
Filed under: Mental Health on September 30th, 2008 | Comments Off
A new study from researchers in Italy reports that endoscopy may not be necessary in children who show no symptoms after a caustic ingestion. The results demonstrated that the incidence of severe abnormalities of the esophagus in children without any early symptoms is very low and an endoscopy could be avoided.
More: continued here
Filed under: GastroIntestinal / Gastroentorology on September 30th, 2008 | Comments Off
Dyax Corp.(NASDAQ:DYAX) announced the completion of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of Dyax’s lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). Dyax has requested Priority Review, which, if granted, would set a target date of six months from receipt of the […]
Filed under: Dermatology on September 30th, 2008 | Comments Off
Cambridge Research Biochemicals (CRB), a specialist in the custom production of polyclonal antibodies, is now expanding its antibody offering to include monoclonal antibody production via two new agreements with Babraham Bioscience Technologies (BBT) and Epitomics Inc. CRB and Cambridge-based BBT have formed an alliance that will enable CRB to market custom […]
Filed under: Biology on September 30th, 2008 | Comments Off
Pancreatic carcinoma is an obstinate disease that is difficult to deal with, the five-year survival rate is 4%. Conventionally, the main treatments for pancreatic cancer are surgery, radiation therapy and chemotherapy. Despite advances in surgical and medical therapy, little effect has been made on the mortality rate of this disease.
More: continued here
Filed under: Stem Cell Research on September 30th, 2008 | Comments Off
Just one year after the IRS issued an extensive overhaul of 403(b) regulations, a recent study reveals that they are impacting healthcare employers’ decisions about their retirement plan administration even more so that the Pension Protection Act of 2006 (PPA). The survey, Retirement Plan Trends in Today’s Healthcare Market - 2008, was conducted by the […]
Filed under: Seniors on September 30th, 2008 | Comments Off
The surgeon’s knife is playing an ever smaller role in the treatment of cancer, as it is replaced by increasingly efficient and safe radiation therapy techniques. Progress in radiation technology will also lead to better detection rates for cancer. This is according to Professor Freek Beekman, who will give his inaugural speech at Delft University […]
Filed under: Radiology on September 30th, 2008 | Comments Off
The European Medicines Agency (EMEA) has been formally notified by UCB Pharma S.A. of its decision to withdraw the application for a centralised marketing authorisation for the medicine Lacosamide Pain UCB Pharma (lacosamide) film-coated tablets. Lacosamide Pain UCB Pharma was expected to be used for the treatment of diabetic neuropathic pain […]
Filed under: Diabetes on September 30th, 2008 | Comments Off
A nipple shield that disinfects milk as it leaves the breast has shown to prevent mother-to-child HIV transmission, BBC News reports. Devised by Stephen Gerrard, a
More: continued here
Filed under: Nutrition / Diet on September 30th, 2008 | Comments Off